-
Angeletti D, Yewdell JW, 2018: Is it possible to develop a puniversalq influenza virus vaccine? Outflanking antibody immunodominance on the road to universal influenza vaccination[J]. Cold Spring Harb Perspect Biol, 10, a028852-. doi: 10.1101/cshperspect.a028852
-
Antrobus RD, Berthoud TK, Mullarkey CE, Hoschler K, Coughlan L, Zambon M, Hill AV, Gilbert SC, 2014a: Coadministration of seasonal influenza vaccine and MVA-NP + M1 simultaneously achieves potent humoral and cell-mediated responses[J]. Mol Ther, 22, 233-238. doi: 10.1038/mt.2013.162
-
Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T, Gilbert SC, 2014b: Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens[J]. Mol Ther, 22, 668-674. doi: 10.1038/mt.2013.284
-
Asthagiri Arunkumar G, McMahon M, Pavot V, Aramouni M, Ioannou A, Lambe T, Gilbert S, Krammer F, 2019: Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice[J]. Vaccine, 37, 5567-5577. doi: 10.1016/j.vaccine.2019.07.095
-
Bajic G, Maron MJ, Adachi Y, Onodera T, McCarthy KR, McGee CE, Sempowski GD, Takahashi Y, Kelsoe G, Kuraoka M, Schmidt AG, 2019: Influenza antigen engineering focuses immune responses to a subdominant but broadly protective viral epitope[J]. Cell Host Microb, 25, e826-.
-
Bangaru S, Lang S, Schotsaert M, Vanderven HA, Zhu X, Kose N, Bombardi R, Finn JA, Kent SJ, Gilchuk P, Gilchuk I, Turner HL, Garcia-Sastre A, Li S, Ward AB, Wilson IA, Crowe JE Jr, 2019: A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface[J]. Cell, 177, e1118-.
-
Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G, 2017: Repeated annual influenza vaccination and vaccine effectiveness: review of evidence[J]. Expert Rev Vaccin, 16, 1-14. doi: 10.1080/14760584.2016.1221347
-
Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, Hill AV, Gilbert SC, 2011: Potent CD8 + T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP + M1[J]. Clin Infect Dis, 52, 1-7. doi: 10.1093/cid/ciq015
-
Boonsathorn N, Panthong S, Koksunan S, Chittaganpitch M, Phuygun S, Waicharoen S, Prachasupap A, Sasaki T, Kubota-Koketsu R, Yasugi M, Ono K, Arai Y, Kurosu T, Sawanpanyalert P, Ikuta K, Watanabe Y, 2014: A human monoclonal antibody derived from a vaccinated volunteer recognizes heterosubtypically a novel epitope on the hemagglutinin globular head of H1 and H9 influenza A viruses[J]. Biochem Biophys Res Commun, 452, 865-870. doi: 10.1016/j.bbrc.2014.09.008
-
Boyoglu-Barnum S, Hutchinson GB, Boyington JC, Moin SM, Gillespie RA, Tsybovsky Y, Stephens T, Vaile JR, Lederhofer J, Corbett KS, Fisher BE, Yassine HM, Andrews SF, Crank MC, McDermott AB, Mascola JR, Graham BS, Kanekiyo M, 2020: Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses[J]. Nat Commun, 11, 791-. doi: 10.1038/s41467-020-14579-4
-
Broecker F, Liu STH, Sun W, Krammer F, Simon V, Palese P, 2018: Immunodominance of antigenic site B in the hemagglutinin of the current H3N2 influenza virus in humans and mice[J]. J Virol, 92, e01100-18.
-
Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A, 2007: Ab and T cell epitopes of influenza A virus, knowledge and opportunities[J]. Proc Natl Acad Sci U S A, 104, 246-251. doi: 10.1073/pnas.0609330104
-
Caton AJ, Brownlee GG, Yewdell JW, Gerhard W, 1982: The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype)[J]. Cell, 31, 417-427. doi: 10.1016/0092-8674(82)90135-0
-
Chen YQ, Wohlbold TJ, Zheng NY, Huang M, Huang Y, Neu KE, Lee J, Wan H, Rojas KT, Kirkpatrick E, Henry C, Palm AE, Stamper CT, Lan LY, Topham DJ, Treanor J, Wrammert J, Ahmed R, Eichelberger MC, Georgiou G, Krammer F, Wilson PC, 2018: Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies[J]. Cell, 173, 417-429.e10. doi: 10.1016/j.cell.2018.03.030
-
Cohen J, 2018: Universal flu vaccine is 'an alchemist's dream'[J]. Science, 362, 1094-. doi: 10.1126/science.362.6419.1094
-
Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, Rupert P, Correnti C, Kalyuzhniy O, Vittal V, Connell MJ, Stevens E, Schroeter A, Chen M, Macpherson S, Serra AM, Adachi Y, Holmes MA, Li Y, Klevit RE, Graham BS, Wyatt RT, Baker D, Strong RK, Crowe JE Jr, Johnson PR, Schief WR, 2014: Proof of principle for epitope-focused vaccine design[J]. Nature, 507, 201-206. doi: 10.1038/nature12966
-
Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JP, Skehel JJ, Lanzavecchia A, 2011: A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins[J]. Science, 333, 850-856. doi: 10.1126/science.1205669
-
De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, Vandekerckhove J, Fiers W, Saelens X, 2008: An influenza A vaccine based on tetrameric ectodomain of matrix protein 2[J]. J Biol Chem, 283, 11382-11387. doi: 10.1074/jbc.M800650200
-
de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD, 2000: Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly[J]. J Med Virol, 61, 94-99. doi: 10.1002/(SICI)1096-9071(200005)61:1<94::AID-JMV15>3.0.CO;2-C
-
Deng L, Wang BZ, 2018: A perspective on nanoparticle universal influenza vaccines[J]. ACS Infect Dis, 4, 1656-1665. doi: 10.1021/acsinfecdis.8b00206
-
Deng L, Cho KJ, Fiers W, Saelens X, 2015: M2e-based universal influenza A vaccines[J]. Vaccin Basel, 3, 105-136. doi: 10.3390/vaccines3010105
-
DiLillo DJ, Tan GS, Palese P, Ravetch JV, 2014: Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo[J]. Nat Med, 20, 143-151. doi: 10.1038/nm.3443
-
Doyle TM, Hashem AM, Li C, Van Domselaar G, Larocque L, Wang J, Smith D, Cyr T, Farnsworth A, He R, Hurt AC, Brown EG, Li X, 2013: Universal anti-neuraminidase antibody inhibiting all influenza A subtypes[J]. Antivir Res, 100, 567-574. doi: 10.1016/j.antiviral.2013.09.018
-
Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJ, Geelen E, Sahin O, Sieuwerts M, Brakenhoff JP, Vogels R, Li OT, Poon LL, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RH, 2012: Highly conserved protective epitopes on influenza B viruses[J]. Science, 337, 1343-1348. doi: 10.1126/science.1222908
-
Du R, Cui Q, Rong L, 2019: Competitive cooperation of hemagglutinin and neuraminidase during influenza A virus entry[J]. Viruses, 11, 458-. doi: 10.3390/v11050458
-
Eggink D, Goff PH, Palese P, 2014: Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain[J]. J Virol, 88, 699-704. doi: 10.1128/JVI.02608-13
-
Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA, 2009: Antibody recognition of a highly conserved influenza virus epitope[J]. Science, 324, 246-251. doi: 10.1126/science.1171491
-
Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, Vogels R, Brakenhoff JP, Kompier R, Koldijk MH, Cornelissen LA, Poon LL, Peiris M, Koudstaal W, Wilson IA, Goudsmit J, 2011: A highly conserved neutralizing epitope on group 2 influenza A viruses[J]. Science, 333, 843-850. doi: 10.1126/science.1204839
-
Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, Khayat R, Lee JH, Dillon MA, OoNeil RE, Faynboym AM, Horowitz M, Horowitz L, Ward AB, Palese P, Webby R, Lerner RA, Bhatt RR, Wilson IA, 2012: Cross-neutralization of influenza A viruses mediated by a single antibody loop[J]. Nature, 489, 526-532. doi: 10.1038/nature11414
-
Eliasson DG, El Bakkouri K, Schon K, Ramne A, Festjens E, Lowenadler B, Fiers W, Saelens X, Lycke N, 2008: CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine[J]. Vaccine, 26, 1243-1252. doi: 10.1016/j.vaccine.2007.12.027
-
Epstein SL, 2006: Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature[J]. J Infect Dis, 193, 49-53. doi: 10.1086/498980
-
Ermler ME, Kirkpatrick E, Sun W, Hai R, Amanat F, Chromikova V, Palese P, Krammer F, 2017: Chimeric hemagglutinin constructs induce broad protection against influenza B virus challenge in the mouse model[J]. J Virol, 91, e00286-17.
-
Farahmand B, Taheri N, Shokouhi H, Soleimanjahi H, Fotouhi F, 2019: Chimeric protein consisting of 3M2e and HSP as a universal influenza vaccine candidate: from in silico analysis to preliminary evaluation[J]. Virus Genes, 55, 22-32. doi: 10.1007/s11262-018-1609-5
-
Florek NW, Weinfurter JT, Jegaskanda S, Brewoo JN, Powell TD, Young GR, Das SC, Hatta M, Broman KW, Hungnes O, Dudman SG, Kawaoka Y, Kent SJ, Stinchcomb DT, Osorio JE, Friedrich TC, 2014: Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques[J]. J Virol, 88, 13418-13428. doi: 10.1128/JVI.01219-14
-
Gerdil C, 2003: The annual production cycle for influenza vaccine[J]. Vaccine, 21, 1776-1779. doi: 10.1016/S0264-410X(03)00071-9
-
Gras S, Kedzierski L, Valkenburg SA, Laurie K, Liu YC, Denholm JT, Richards MJ, Rimmelzwaan GF, Kelso A, Doherty PC, Turner SJ, Rossjohn J, Kedzierska K, 2010: Cross-reactive CD8 + T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses[J]. Proc Natl Acad Sci U S A, 107, 12599-12604. doi: 10.1073/pnas.1007270107
-
Grayson KJ, Anderson JLR, 2018: Designed for life: biocompatible de novo designed proteins and components[J]. J R Soc Interface, 15, 20180472-. doi: 10.1098/rsif.2018.0472
-
Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, Salimi N, Vita R, Ponomarenko J, Scheuermann RH, Sette A, Peters B, 2009: Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population[J]. Proc Natl Acad Sci U S A, 106, 20365-20370. doi: 10.1073/pnas.0911580106
-
Hai R, Krammer F, Tan GS, Pica N, Eggink D, Maamary J, Margine I, Albrecht RA, Palese P, 2012: Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes[J]. J Virol, 86, 5774-5781. doi: 10.1128/JVI.00137-12
-
Hayward AC, Wang L, Goonetilleke N, Fragaszy EB, Bermingham A, Copas A, Dukes O, Millett ER, Nazareth I, Nguyen-Van-Tam JS, Watson JM, Zambon M, Johnson AM, McMichael AJ, 2015: Natural T cell-mediated protection against seasonal and pandemic influenza[J]. Results of the flu watch cohort study. Am J Respir Crit Care Med, 191, 1422-1431. doi: 10.1164/rccm.201411-1988OC
-
He W, Mullarkey CE, Duty JA, Moran TM, Palese P, Miller MS, 2015: Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones[J]. J Virol, 89, 3610-3618. doi: 10.1128/JVI.03099-14
-
Heaton NS, Sachs D, Chen CJ, Hai R, Palese P, 2013: Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins[J]. Proc Natl Acad Sci U S A, 110, 20248-20253. doi: 10.1073/pnas.1320524110
-
Henry C, Palm AE, Krammer F, Wilson PC, 2018: From original antigenic sin to the universal influenza virus vaccine[J]. Trends Immunol, 39, 70-79. doi: 10.1016/j.it.2017.08.003
-
Huang Y, Owino SO, Crevar CJ, Carter DM, Ross TM, 2019: N-linked glycans and K147 residue on hemagglutinin synergize to elicit broadly-reactive H1N1 influenza antibodies[J]. J Virol, , -.
-
Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X, Hoffman RM, van Meersbergen R, Huizingh J, Wanningen P, Verspuij J, de Man M, Ding Z, Apetri A, Kukrer B, Sneekes-Vriese E, Tomkiewicz D, Laursen NS, Lee PS, Zakrzewska A, Dekking L, Tolboom J, Tettero L, van Meerten S, Yu W, Koudstaal W, Goudsmit J, Ward AB, Meijberg W, Wilson IA, Radosevic K, 2015: A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen[J]. Science, 349, 1301-1306. doi: 10.1126/science.aac7263
-
Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, de Rose R, Winnall WR, Stratov I, Brooks AG, Reading PC, Kent SJ, 2013a: Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies[J]. J Immunol, 190, 1837-1848. doi: 10.4049/jimmunol.1201574
-
Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ, 2013b: Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques[J]. J Virol, 87, 5512-5522. doi: 10.1128/JVI.03030-12
-
Jegaskanda S, Reading PC, Kent SJ, 2014: Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine[J]. J Immunol, 193, 469-475. doi: 10.4049/jimmunol.1400432
-
Jegaskanda S, Andrews SF, Wheatley AK, Yewdell JW, McDermott AB, Subbarao K, 2019: Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines[J]. JCI Insight, 4, e129035-. doi: 10.1172/jci.insight.129035
-
Kanekiyo M, Joyce MG, Gillespie RA, Gallagher JR, Andrews SF, Yassine HM, Wheatley AK, Fisher BE, Ambrozak DR, Creanga A, Leung K, Yang ES, Boyoglu-Barnum S, Georgiev IS, Tsybovsky Y, Prabhakaran MS, Andersen H, Kong W-P, Baxa U, Zephir KL, Ledgerwood JE, Koup RA, Kwong PD, Harris AK, McDermott AB, Mascola JR, Graham BS, 2019: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses[J]. Nat Immunol, 20, 362-372. doi: 10.1038/s41590-018-0305-x
-
Kim MC, Song JM, Eunju O, Kwon YM, Lee YJ, Compans RW, Kang SM, 2013: Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus[J]. Mol Ther, 21, 485-492. doi: 10.1038/mt.2012.246
-
Koutsakos M, Wheatley AK, Loh L, Clemens EB, Sant S, Nussing S, Fox A, Chung AW, Laurie KL, Hurt AC, Rockman S, Lappas M, Loudovaris T, Mannering SI, Westall GP, Elliot M, Tangye SG, Wakim LM, Kent SJ, Nguyen THO, Kedzierska K, 2018: Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity[J]. Sci Transl Med, 10, eaan8405-. doi: 10.1126/scitranslmed.aan8405
-
Koutsakos M, Illing PT, Nguyen THO, Mifsud NA, Crawford JC, Rizzetto S, Eltahla AA, Clemens EB, Sant S, Chua BY, Wong CY, Allen EK, Teng D, Dash P, Boyd DF, Grzelak L, Zeng W, Hurt AC, Barr I, Rockman S, Jackson DC, Kotsimbos TC, Cheng AC, Richards M, Westall GP, Loudovaris T, Mannering SI, Elliott M, Tangye SG, Wakim LM, Rossjohn J, Vijaykrishna D, Luciani F, Thomas PG, Gras S, Purcell AW, Kedzierska K, 2019: Human CD8(+) T cell cross-reactivity across influenza A, B and C viruses[J]. Nat Immunol, 20, 613-625. doi: 10.1038/s41590-019-0320-6
-
Krammer F, 2019: The human antibody response to influenza A virus infection and vaccination[J]. Nat Rev Immunol, 19, 383-397. doi: 10.1038/s41577-019-0143-6
-
Krammer F, Palese P, 2015: Advances in the development of influenza virus vaccines[J]. Nat Rev Drug Discov, 14, 167-182. doi: 10.1038/nrd4529
-
Krammer F, Palese P, 2019: Universal influenza virus vaccines that target the conserved hemagglutinin stalk and conserved sites in the head domain[J]. J Infect Dis, 219, S62-S67. doi: 10.1093/infdis/jiy711
-
Krammer F, Pica N, Hai R, Margine I, Palese P, 2013: Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies[J]. J Virol, 87, 6542-6550. doi: 10.1128/JVI.00641-13
-
Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC, Palese P, Shaw ML, Treanor J, Webster RG, Garcia-Sastre A, 2018: Influenza[J]. Nat Rev Dis Primers, 4, 3-. doi: 10.1038/s41572-018-0002-y
-
Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Albrecht R, Blum DL, Ramos I, Fernandez-Sesma A, Edwards KM, Garcia-Sastre A, Basler CF, Crowe JE Jr, 2012: Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses[J]. J Virol, 86, 6334-6340. doi: 10.1128/JVI.07158-11
-
Lambe T, Carey JB, Li Y, Spencer AJ, van Laarhoven A, Mullarkey CE, Vrdoljak A, Moore AC, Gilbert SC, 2013: Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1[J]. Sci Rep, 3, 1443-. doi: 10.1038/srep01443
-
Lee PS, Yoshida R, Ekiert DC, Sakai N, Suzuki Y, Takada A, Wilson IA, 2012: Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity[J]. Proc Natl Acad Sci U S A, 109, 17040-17045. doi: 10.1073/pnas.1212371109
-
Lee PS, Ohshima N, Stanfield RL, Yu W, Iba Y, Okuno Y, Kurosawa Y, Wilson IA, 2014: Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus[J]. Nat Commun, 5, 3614-. doi: 10.1038/ncomms4614
-
Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, Lee JH, Huang M, Qu X, Edupuganti S, Mulligan M, Das SR, Yewdell JW, Mehta AK, Wilson PC, Ahmed R, 2012: Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells[J]. Proc Natl Acad Sci U S A, 109, 9047-9052. doi: 10.1073/pnas.1118979109
-
Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, Sheehy SH, Havelock T, Faust SN, Williams RL, Gilbert A, Oxford J, Dong T, Hill AV, Gilbert SC, 2012: Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP + M1, in humans[J]. Clin Infect Dis, 55, 19-25. doi: 10.1093/cid/cis327
-
Lin SC, Lin YF, Chong P, Wu SC, 2012: Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles[J]. PLoS ONE, 7, e39075-. doi: 10.1371/journal.pone.0039075
-
Liu W, Li H, Chen YH, 2003: N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication[J]. FEMS Immunol Med Microbiol, 35, 141-146. doi: 10.1016/S0928-8244(03)00009-9
-
Liu STH, Behzadi MA, Sun W, Freyn AW, Liu WC, Broecker F, Albrecht RA, Bouvier NM, Simon V, Nachbagauer R, Krammer F, Palese P, 2018: Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance[J]. J Clin Invest, 128, 4992-4996. doi: 10.1172/JCI122895
-
Lu Y, Welsh JP, Swartz JR, 2014: Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines[J]. Proc Natl Acad Sci U S A, 111, 125-130. doi: 10.1073/pnas.1308701110
-
Mallajosyula VV, Citron M, Ferrara F, Lu X, Callahan C, Heidecker GJ, Sarma SP, Flynn JA, Temperton NJ, Liang X, Varadarajan R, 2014: Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection[J]. Proc Natl Acad Sci U S A, 111, E2514-E2523. doi: 10.1073/pnas.1402766111
-
Mandala VS, Liao SY, Gelenter MD, Hong M, 2019: The Transmembrane conformation of the influenza B virus M2 protein in lipid bilayers[J]. Sci Rep, 9, 3725-. doi: 10.1038/s41598-019-40217-1
-
Margine I, Krammer F, Hai R, Heaton NS, Tan GS, Andrews SA, Runstadler JA, Wilson PC, Albrecht RA, Garcia-Sastre A, Palese P, 2013: Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses[J]. J Virol, 87, 10435-10446. doi: 10.1128/JVI.01715-13
-
McMichael AJ, Gotch FM, Noble GR, Beare PA, 1983: Cytotoxic T-cell immunity to influenza[J]. N Engl J Med, 309, 13-17. doi: 10.1056/NEJM198307073090103
-
Memoli MJ, Han A, Walters KA, Czajkowski L, Reed S, Athota R, Rosas LA, Cervantes-Medina A, Park JK, Morens DM, Kash JC, Taubenberger JK, 2019: Influenza A reinfection in sequential human challenge: implications for protective immunity and puniversalq vaccine development[J]. Clin Infect Dis, , -.
-
Mesin L, Schiepers A, Ersching J, Barbulescu A, Cavazzoni CB, Angelini A, Okada T, Kurosaki T, Victora GD, 2020: Restricted clonality and limited germinal center reentry characterize memory B cell reactivation by boosting[J]. Cell, 180, 92-106. doi: 10.1016/j.cell.2019.11.032
-
Mezhenskaya D, Isakova-Sivak I, Rudenko L, 2019: M2e-based universal influenza vaccines: a historical overview and new approaches to development[J]. J Biomed Sci, 26, 76-. doi: 10.1186/s12929-019-0572-3
-
Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, Basler CF, Palese P, 2013: 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans[J]. J Infect Dis, 207, 98-105. doi: 10.1093/infdis/jis652
-
Monto AS, Kendal AP, 1973: Effect of neuraminidase antibody on Hong Kong influenza[J]. Lancet, 1, 623-625.
-
Murphy BR, Kasel JA, Chanock RM, 1972: Association of serum anti-neuraminidase antibody with resistance to influenza in man[J]. N Engl J Med, 286, 1329-1332. doi: 10.1056/NEJM197206222862502
-
Nachbagauer R, Krammer F, 2017: Universal influenza virus vaccines and therapeutic antibodies[J]. Clin Microbiol Infect, 23, 222-228. doi: 10.1016/j.cmi.2017.02.009
-
Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W, 1999: A universal influenza A vaccine based on the extracellular domain of the M2 protein[J]. Nat Med, 5, 1157-1163. doi: 10.1038/13484
-
Okuno Y, Isegawa Y, Sasao F, Ueda S, 1993: A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains[J]. J Virol, 67, 2552-2558. doi: 10.1128/JVI.67.5.2552-2558.1993
-
Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, Tan GS, Krause JC, Moran T, Stein CR, Banach D, Wrammert J, Belshe RB, Garcia-Sastre A, Palese P, 2012: Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses[J]. Proc Natl Acad Sci U S A, 109, 2573-2578. doi: 10.1073/pnas.1200039109
-
Poon LLM, Leung YHC, Nicholls JM, Perera P-Y, Lichy JH, Yamamoto M, Waldmann TA, Peiris JSM, Perera LP, 2009: Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice[J]. J Immunol Baltim Md 1950, 182, 3063-3071.
-
Quinones-Parra S, Grant E, Loh L, Nguyen TH, Campbell KA, Tong SY, Miller A, Doherty PC, Vijaykrishna D, Rossjohn J, Gras S, Kedzierska K, 2014: Preexisting CD8 + T-cell immunity to the H7N9 influenza A virus varies across ethnicities[J]. Proc Natl Acad Sci U S A, 111, 1049-1054. doi: 10.1073/pnas.1322229111
-
Riedel T, Ghasparian A, Moehle K, Rusert P, Trkola A, Robinson JA, 2011: Synthetic virus-like particles and conformationally constrained peptidomimetics in vaccine design[J]. ChemBioChem, 12, 2829-2836. doi: 10.1002/cbic.201100586
-
Schulman JL, Khakpour M, Kilbourne ED, 1968: Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice[J]. J Virol, 2, 778-786. doi: 10.1128/JVI.2.8.778-786.1968
-
Sesterhenn F, Galloux M, Vollers SS, Csepregi L, Yang C, Descamps D, Bonet J, Friedensohn S, Gainza P, Corthésy P, Chen M, Rosset S, Rameix-Welti MA, Éléouët JF, Reddy ST, Graham BS, Riffault S, Correia BE, 2019: Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen[J]. PLoS Biol, 17, e3000164-. doi: 10.1371/journal.pbio.3000164
-
Sesterhenn F, Yang C, Bonet J, Cramer JT, Wen X, Wang Y, Chiang CI, Abriata LA, Kucharska I, Castoro G, Vollers SS, Galloux M, Dheilly E, Rosset S, Corthésy P, Georgeon S, Villard M, Richard CA, Descamps D, Delgado T, Oricchio E, Rameix-Welti MA, Más V, Ervin S, Eléouët JF, Riffault S, Bates JT, Julien JP, Li Y, Jardetzky T, Krey T, Correia BE, 2020: De novo protein design enables the precise induction of RSV-neutralizing antibodies[J]. Science, 368, eaay5051-. doi: 10.1126/science.aay5051
-
Sheikh QM, Gatherer D, Reche PA, Flower DR, 2016: Towards the knowledge-based design of universal influenza epitope ensemble vaccines[J]. Bioinform Oxf Engl, 32, 3233-3239. doi: 10.1093/bioinformatics/btw399
-
Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A, 2013: Cellular immune correlates of protection against symptomatic pandemic influenza[J]. Nat Med, 19, 1305-1312. doi: 10.1038/nm.3350
-
Stadlbauer D, Zhu X, McMahon M, Turner JS, Wohlbold TJ, Schmitz AJ, Strohmeier S, Yu W, Nachbagauer R, Mudd PA, Wilson IA, Ellebedy AH, Krammer F, 2019: Broadly protective human antibodies that target the active site of influenza virus neuraminidase[J]. Science, 366, 499-504. doi: 10.1126/science.aay0678
-
Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, Garcia-Sastre A, Palese P, 2010: Influenza virus vaccine based on the conserved hemagglutinin stalk domain[J]. MBio, 1, e00018-10.
-
Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA, 2009: Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses[J]. Nat Struct Mol Biol, 16, 265-273. doi: 10.1038/nsmb.1566
-
Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, Huang CY, Liddington RC, Beigel JH, Marasco WA, 2011: Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies[J]. Clin Infect Dis, 52, 1003-1009. doi: 10.1093/cid/cir121
-
Sun W, Kirkpatrick E, Ermler M, Nachbagauer R, Broecker F, Krammer F, Palese P, 2019: Development of influenza B universal vaccine candidates using the pMosaicq hemagglutinin approach[J]. J Virol, 93, e00333-19.
-
Terajima M, Cruz J, Co MD, Lee JH, Kaur K, Wrammert J, Wilson PC, Ennis FA, 2011: Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies[J]. J Virol, 85, 13463-13467. doi: 10.1128/JVI.05193-11
-
Tobler K, Kelly ML, Pinto LH, Lamb RA, 1999: Effect of cytoplasmic tail truncations on the activity of the M(2) ion channel of influenza A virus[J]. J Virol, 73, 9695-9701. doi: 10.1128/JVI.73.12.9695-9701.1999
-
Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR, 1990: Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice[J]. J Virol, 64, 1375-1377. doi: 10.1128/JVI.64.3.1375-1377.1990
-
Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A, 2011: Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults[J]. Vaccine, 29, 5145-5152.
-
Valkenburg SA, Li OTW, Li A, Bull M, Waldmann TA, Perera LP, Peiris M, Poon LLM, 2018: Protection by universal influenza vaccine is mediated by memory CD4 T cells[J]. Vaccine, 36, 4198-4206. doi: 10.1016/j.vaccine.2018.06.007
-
Wan H, Gao J, Xu K, Chen H, Couzens LK, Rivers KH, Easterbrook JD, Yang K, Zhong L, Rajabi M, Ye J, Sultana I, Wan XF, Liu X, Perez DR, Taubenberger JK, Eichelberger MC, 2013: Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses[J]. J Virol, 87, 9290-9300. doi: 10.1128/JVI.01203-13
-
Wang TT, Palese P, 2011: Biochemistry. Catching a moving target[J]. Science, 333, 834-835.
-
Wang Z, Wan Y, Qiu C, Quinones-Parra S, Zhu Z, Loh L, Tian D, Ren Y, Hu Y, Zhang X, Thomas PG, Inouye M, Doherty PC, Kedzierska K, Xu J, 2015: Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8(+) T cells[J]. Nat Commun, 6, 6833-. doi: 10.1038/ncomms7833
-
Wang Z, Zhu L, Nguyen THO, Wan Y, Sant S, Quinones-Parra SM, Crawford JC, Eltahla AA, Rizzetto S, Bull RA, Qiu C, Koutsakos M, Clemens EB, Loh L, Chen T, Liu L, Cao P, Ren Y, Kedzierski L, Kotsimbos T, McCaw JM, La Gruta NL, Turner SJ, Cheng AC, Luciani F, Zhang X, Doherty PC, Thomas PG, Xu J, Kedzierska K, 2018: Clonally diverse CD38(+)HLA-DR(+)CD8(+) T cells persist during fatal H7N9 disease[J]. Nat Commun, 9, 824-. doi: 10.1038/s41467-018-03243-7
-
Wanitchang A, Wongthida P, Jongkaewwattana A, 2016: Influenza B virus M2 protein can functionally replace its influenza A virus counterpart in promoting virus replication[J]. Virology, 498, 99-108. doi: 10.1016/j.virol.2016.08.016
-
Watanabe A, McCarthy KR, Kuraoka M, Schmidt AG, Adachi Y, Onodera T, Tonouchi K, Caradonna TM, Bajic G, Song S, McGee CE, Sempowski GD, Feng F, Urick P, Kepler TB, Takahashi Y, Harrison SC, Kelsoe G, 2019: Antibodies to a conserved influenza head interface epitope protect by an IgG subtype-dependent mechanism[J]. Cell, 177, e1116-.
-
Weidenbacher PA, Kim PS, 2019: Protect, modify, deprotect (PMD): a strategy for creating vaccines to elicit antibodies targeting a specific epitope[J]. Proc Natl Acad Sci U S A, 116, 9947-9952. doi: 10.1073/pnas.1822062116
-
Wilkinson TM, Li CKF, Chui CSC, Huang AKY, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, Staples KJ, Dong T, Douek DC, McMichael AJ, Xu X-N, 2012: Preexisting influenza-specific CD4 + T cells correlate with disease protection against influenza challenge in humans[J]. Nat Med, 18, 274-280. doi: 10.1038/nm.2612
-
Wilson JR, Guo Z, Reber A, Kamal RP, Music N, Gansebom S, Bai Y, Levine M, Carney P, Tzeng WP, Stevens J, York IA, 2016: An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo[J]. Antivir Res, 135, 48-55. doi: 10.1016/j.antiviral.2016.10.001
-
Wohlbold TJ, Podolsky KA, Chromikova V, Kirkpatrick E, Falconieri V, Meade P, Amanat F, Tan J, tenOever BR, Tan GS, Subramaniam S, Palese P, Krammer F, 2017: Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes[J]. Nat Microbiol, 2, 1415-1424. doi: 10.1038/s41564-017-0011-8
-
World Health Organization (WHO) (2018) 2018 Influenza (seasonal) fact sheet. WHO, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed 6 June 2020
-
Worobey M, Plotkin S, Hensley SE, 2020: Influenza vaccines delivered in early childhood could turn antigenic sin into antigenic blessings[J]. Cold Spring Harb Perspect Med, , -.
-
Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, OoDonnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC, 2011: Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection[J]. J Exp Med, 208, 181-193. doi: 10.1084/jem.20101352
-
Wu Y, Gao GF, 2019: pBreathingq hemagglutinin reveals cryptic epitopes for universal influenza vaccine design[J]. Cell, 177, 1086-1088. doi: 10.1016/j.cell.2019.04.034
-
Wu NC, Wilson IA, 2018: Structural insights into the design of novel anti-influenza therapies[J]. Nat Struct Mol Biol, 25, 115-121. doi: 10.1038/s41594-018-0025-9
-
Yao Y, Wang H, Chen J, Shao Z, He B, Lan J, Chen Q, Chen Z, 2019: Protection against homo and hetero-subtypic in fluenza A virus by optimized M2e DNA vaccine[J]. Emerg Microb Infect, 8, 45-54. doi: 10.1080/22221751.2018.1558962
-
Yassine HM, Boyington JC, McTamney PM, Wei CJ, Kanekiyo M, Kong WP, Gallagher JR, Wang L, Zhang Y, Joyce MG, Lingwood D, Moin SM, Andersen H, Okuno Y, Rao SS, Harris AK, Kwong PD, Mascola JR, Nabel GJ, Graham BS, 2015: Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection[J]. Nat Med, 21, 1065-1070. doi: 10.1038/nm.3927
-
Zebedee SL, Lamb RA, 1989: Growth restriction of influenza A virus by M2 protein antibody is genetically linked to the M1 protein[J]. Proc Natl Acad Sci U S A, 86, 1061-1065. doi: 10.1073/pnas.86.3.1061
-
Zerbe K, Moehle K, Robinson JA, 2017: Protein epitope mimetics: from new antibiotics to supramolecular synthetic vaccines[J]. Acc Chem Res, 50, 1323-1331. doi: 10.1021/acs.accounts.7b00129